Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence.

ABSTRACT: Bladder cancer is the fourth most common cancer among men in the United States and more than half of patients experience recurrences within 5 years after initial diagnosis. Additional clinically informative and actionable biomarkers of the recurrent bladder cancer phenotypes are needed to improve screening and molecular therapeutic approaches for recurrence prevention. MicroRNA-34a (miR-34a) is a short noncoding regulatory RNA with tumor suppressive attributes. We leveraged our unique, large, population-based prognostic study of bladder cancer in New Hampshire, United States to evaluate miR-34a expression levels in individual tumor cells to assess prognostic value. We collected detailed exposure and medical history data, as well as tumor tissue specimens from bladder patients and followed

SUBMITTER: Andrew AS 

PROVIDER: S-EPMC4485975 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature